Regulatory Story
Go to market news section View chart   Print
ABCAM Plc  -  ABC   

Notification of Interim Results

Released 07:00 12-Feb-2013

RNS Number : 6443X
12 February 2013

For immediate release

12 February 2013




("Abcam" or the "Company")


Notification of Interim Results


Cambridge, UK: Abcam plc (AIM: ABC), a global leader in the supply of protein research tools, will announce its interim results for the six months ended 31 December 2012 on Tuesday 5 March 2013.


A briefing for analysts will be held at 10.30am on the morning of the results at the offices of Buchanan, 107 Cheapside, London, EC2V 6DN.



For further information:



+ 44 (0) 1223 696 000

Jonathan Milner, Chief Executive Officer

Jeff Iliffe, Chief Financial Officer


Numis Securities - Nominated Adviser & Joint Broker

+ 44 (0) 20 7260 1000

Michael Meade / Nick Westlake - Nominated Adviser

James Black - Corporate Broking

Peel Hunt LLP - Joint Broker

+ 44 (0) 207 418 8900

Andy Crossley - Corporate Broking


+ 44 (0) 20 7466 5000

Mark Court / Fiona Henson / Sophie Cowles


Notes to editors:


About Abcam plc


Abcam is a producer and distributor of high quality protein research tools. These tools enable life scientists to analyse components of living cells at the molecular level, which is essential in understanding health and disease.

Headquartered in Cambridge (UK), Abcam has subsidiary offices in Bristol (UK), Cambridge, MA (USA), Eugene, OR (USA), San Francisco, CA (USA), Tokyo (Japan), Hangzhou and Hong Kong (both in China), allowing it to serve a global customer base in over 130 countries. Abcam employs over 680 staff across its eight operating companies.

 At 31 December 2012 Abcam had an online catalogue of over 102,000 products sourced from more than 400 suppliers. The catalogue includes a growing range of non-primary antibody products such as secondaries, proteins, peptides, lysates, immunoassays and other kits. Products are available for life science research and distributed to academic and commercial users. A highly developed eCommerce platform, which includes regional websites for the Chinese and Japanese markets, allows customers to access up-to-date and detailed technical product data sheets at the Company's website,

Abcam was admitted to AIM in November 2005 and trades under the ticker symbol ABC. The Company's vision is to be the world's leading life science reagents company.

This information is provided by RNS
The company news service from the London Stock Exchange

London Stock Exchange plc is not responsible for and does not check content on this Website. Website users are responsible for checking content. Any news item (including any prospectus) which is addressed solely to the persons and countries specified therein should not be relied upon other than by such persons and/or outside the specified countries. Terms and conditions, including restrictions on use and distribution apply.


Notification of Interim Results - RNS